Results 101 to 110 of about 584,093 (236)

SEPARATION OF SULFONYLUREA METABOLITES IN WATER BY CAPILLARY ELECTROPHORESIS

open access: yes, 1995
The potential of capillary electrophoresis (CE) for the separation and detection of the metabolites of nine sulfonylurea herbicides in aqueous solution was evaluated.
VICARI A, BONETTI A, DINELLI G
core   +1 more source

Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese Cohort

open access: yesLiver International Communications, Volume 7, Issue 4, December 2026.
ABSTRACT Aim Metabolic syndrome (MetS) is a known risk factor for hepatocellular carcinoma (HCC), but the impact of cumulative MetS burden and changes in MetS status over time remains unclear. This study aimed to assess these associations using a large‐scale Japanese health dataset.
Yutaka Yata   +9 more
wiley   +1 more source

Pharmaco-topology of Sulfonylurea Receptors [PDF]

open access: yesJournal of Biological Chemistry, 2000
Andrey P. Babenko   +2 more
openaire   +1 more source

Additive Glucagonotropic and Insulinotropic Effects of Glucose‐Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11095-11106, December 2026.
ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe   +13 more
wiley   +1 more source

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11086-11094, December 2026.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi   +7 more
wiley   +1 more source

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes : a meta-analysis

open access: yes, 2012
OBJECTIVE: Oral antidiabetic drugs (including metformin and sulfonylurea) may play a role in the relationship between type 2 diabetes and cancer. To quantify the association between metformin and sulfonylurea and the risk of cancer, we performed a meta-
Zambon A   +26 more
core   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11394-11406, December 2026.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran   +3 more
wiley   +1 more source

Insulin or sulfonylurea treatments of the diabetics differentially affect erythrocyte membrane and serum enzymes and extent of protein glycosylation

open access: yes, 2001
Erythrocyte membrane protein glycosylation increase by 3.4 fold in diabetes. Insulin or sulfonylurea treatment did not reduce the extent of glycosylation. The serum protein glycosylation was comparable in all the groups including control.
Patel, T. H   +2 more
core   +1 more source

Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011–2014

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11808-11820, December 2026.
ABSTRACT Aims Metformin, the first‐line treatment for Type 2 diabetes mellitus (T2DM), may be neuroprotective but also lowers serum vitamin B12 by ~19%, raising concern that B12 depletion could offset this benefit. We used modern exploratory causal mediation methods in a nationally representative sample to test whether vitamin B12 and methylmalonic ...
Danial Fotros   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy